Company intelligence / Profile preview
DUSA Pharmaceuticals
Wilmington, Massachusetts, United Statesdusapharma.com ↗
- Ownership
- Private
- Employees
- ~59
- Development stage
- Other
01
Overview
DUSA developed and commercialized Levulan Kerastick (aminolevulinic acid HCl) for use with the BLU-U device as an FDA-approved photodynamic therapy for actinic keratoses of the face/scalp. The company also marketed BLU-U for moderate inflammatory acne vulgaris. Both products remain available under Sun Pharma's ownership. Clinical trials supported their efficacy.
- Therapeutic areas
- Dermatology
- Modalities
- Small moleculeDevice
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
None specifically noted post-acquisition.
Beyond the preview
Go deeper on DUSA Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DUSA Pharmaceuticals.